Jingu Financial News | The contract research organizations concept rises across the board, with wuxi bio (02269) up 7.48%, wuxi apptec (02359) up 6.12%, pharmaron (03759) up 2.8%, genscript bio (01548) up 1.87%, and asymchem laboratories (06821) up 1.44%.

Zhongtai research reports indicate that in early November, the pharmaceutical industry, which was at a low point, experienced a strong rebound, followed by a fluctuation and adjustment in the large cap. Within the sector, spurred by policies such as medical insurance prepayments and the release of the medical insurance catalog, the pharmaceutical commerce and innovative drugs sub-sectors both performed well. The warming of medical insurance policies is expected to alleviate the core suppressive factors in the pharmaceutical sector, and combined with industry comparisons and fund hold positions, there is significant upward elasticity in the sector. The report states that, from this year’s perspective, active pharmaceutical ingredients, low consumption, and certain upstream stocks have shown certain improvements first; looking ahead to next year, the trends in active pharmaceutical ingredients and low consumption are expected to continue, while CRO/CDMO, upstream, ICL, and equipment bidding may gradually show significant turning points.